A potentially cost-effective strategy for gene therapy of hemophilia B is to create universal factor IX-secreting cell lines suitable for imptantation into different patients. To avoid graft rejection, the implanted cells are enclosed in alginatepolylysine-alginate microcapsules that are permeable to factor IX diffusion, but impermeable to the hosts' immune mediators. This nonautologous approach was assessed by implanting encapsulated mouse myoblasts secreting human factor IX into allogeneic mice. Human factor IX was detected in the mouse plasma for up to 14 days maximally at a 4 ng/ mL. Antibodies to human factor IX were detected after 3 weeks at escalating levels, which were sustained through-
EMOPHILIA B IS AN X-linked bleeding disorder
caused by clotting factor IX (FTX) deficiency' and affects 1 in 30,000 males. Although the bleeding resulting from FIX deficiency is controlled with FIX concentrate infusions, severe long-term disabilities and life-threatening episodes may still occur. Furthermore, the life-long treatment with plasma-derived FIX has the risk of viral infections (such as human immunodeficiency virus [HIV] or hepatitis C). Somatic gene therapy for delivering a constant, therapeutic level of human FIX (hFIX) is an attractive alternative treatment of hemophilia B. Current ex vivo gene therapy protocols are often based on autologous cell implantations.* However, the need to modify genetically each patient's cell is labor-intensive and likely to be costly. Furthermore, the limited availability of recombinant cells from each patient may preclude the necessary quality control tests to meet industrial safety standards.
An alternative approach of nonautologous somatic gene therapy that bypasses some of the above concerns has been pr~posed.~ Instead of engineering autologous cells to secrete FIX, we envisioned creating universal FIX-secreting cell lines that can be implanted in different patients by enclosing these cells in imrnuno-isolation devices such as microcapsules. The encapsulated cells are protected from both humoral and cellular immune responses of the host to minimize rejection: The availability of capsule biomaterial and cultured cell lines will allow verification to meet standards for safety and efficacy.
Several types of biomaterials, such as the water soluble hydrogel, alginate, or synthetic acrylic polymers have been used as vehicles to implant nonautologous islet cells?6 hepatocytes?' and transformed cell lines such as PC129 or Chinese hamster ovary (CHO) cells.'' The feasibility of delivering recombinant gene products in vivo with such immuno-isolation devices has been demonstrated recently. Mouse Ltk-fibroblasts transfected with the human growth hormone gene and encapsulated within alginate microcapsules were able to deliver 0.5 to 1.5 ng of human growth hormone per milliliter of plasma in implanted mice." To adapt this technology to the treatment of hemophilia B, we showed that biologically active and properly processed hFIX can be delivered from the microcapsules containing hFIX secreting Ltk-fibroblasts in vitro." However, the viability of the L&-cells decreased significantly with time as the cells proliferated to fill the microcapsules. Rate limiting exchange of nutrient and metabolic waste at the center core of the cell mass might have led to necrosis and cell death.
A potential solution to the loss of proliferative efficiency of fibroblast cell lines is the encapsulation of myoblasts, which are muscle stem cells that can differentiate into myotubes in vitro.13 Encapsulated myoblasts appeared to survive better than fibroblasts in the microcapsules. At 6 months postimplantation, viability of encapsulated myoblasts remained at >60%,14 whereas the viability of encapsulated fibroblasts was already reduced to <50% by day 80 postimplantation." It is possible that myoblasts can differentiate terminally into myotubes after encapsulation, thus avoiding the gradual loss of viability of encapsulated fibroblasts that continue to divide. Additionally, myoblasts have been shown to perform all the complex posttranslational modifications, including y-carboxylation, required to produce biologically active hFIX.I5 Exploiting these potential advantages of myoblasts for nonautologous somatic gene therapy, we now report the feasibility of delivering hFIX in vivo in mice with microencapsulated myoblasts engineered to secrete hFIX.
MATERIALS AND METHODS
Tissue culture conditions. Mouse C2C12 myoblasts were obtained from American Tissue Culture Collection (ATCC; Rockville, MD, #C% 1772) and cultured under standard conditions in Dulbec-
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HORTELANO ET AL CO's modified essential medium (DMEM) containing glucose (4.5 g n ) , 1 % penicillin and streptomycin (GIBCO, Burlington, Canada), and 10% fetal bovine serum (GIBCO). After reaching confluency, cells were cultured in DMEM medium containing 2% horse serum for 2 to 3 days to induce differentiation into myotubes (which have distinct microscopic morphology). Myoblasts in microcapsules were cultured in vitro in 100-mm dishes, with 3 mL of capsules per 10 mL of medium under the same conditions.
Transfection of myoblasts with hFIXcDNA. Mouse C2C12 myoblasts were transfected by the calcium phosphate precipitation methodI6 with pLIXSNL vector (a gift from Dr A. Dusty Miller, Fred Hutchinson Cancer Research Center, Seattle, WA) containing the hFIX cDNA under the control of the viral LTR promoter" and the Neo gene confemng resistance to G418.'8 Additionally, pKL444-hFIX was used similarly to transfect C2C12 myoblast. This vector was obtained by cloning the hFIX cDNA as a 1.6-kb HindnI fragment from pLNCIXL," a gift from Dr A. Dusty Miller, into the Hind11 site of downstream from the human P-actin promoter. Individual recombinant clones were isolated after selection in G418 (400 pg/mL). Except where otherwise indicated, clone MLhFIX-5D5 from transfection with pLIXSNL was used throughout this study for its vigorous growth and good level of hFIX expression. Clone MPhFIX-D6 was selected from the transfection with pKL444-hFIX.
Enclosure of recombinant myoblasts in microcapsules. Encapsulation of recombinant myoblasts was performed as described earlie?' with minor modifications. Briefly, a suspension of cells was mixed with 1.5% potassium alginate (Kelmar, Kelco Inc, Chicago, IL) in a syringe and extruded through a 27 G needle with a syringe pump (39.3 mLih). An air-jet concentric to the needle created fine droplets of the celValginate mixture that were collected in a 1.1% CaCI2 solution. Upon contact, the droplets gelled. The outer alginate layer was chemically cross-linked with poly-L-lysine hydrobromide (PLL, mol wt: 15,000 to 30,000, Sigma, St Louis, MO) for 6 minutes and then with another layer of alginate. Finally, the remaining free alginate core was dissolved with sodium citrate for 6 minutes to yield microcapsules of ~5 0 0 pm in diameter with an alginate-PLLalginate membrane containing cells.
Implantation of microcapsules into mice. Normal male C57BU 6 mice (Charles River, Montreal, Canada) were implanted with microcapsules enclosing factor IX-secreting myoblasts. The microcapsules were washed in Hank's solution (GIBCO) just before implantation. The animals were anesthetized using a small-animals anesthetic machine (Med-Vet, Toronto, Ontario) providing a controlled amount of isofluorane (Anaquest, Mississauga, Ontario), oxygen, and nitrous oxide. The implantation procedure was done using intravenous (IV) Catheter (Angiocath, 16 G) introduced into the peritoneal cavity through a valvular course to avoid regurgitation. The whole procedure took about 5 minutes, and the animals were soon freely mobile in their cages. Animals were implanted either with 3 mL (8 X 105 cells) or 18 mL (5 X 10' cells) of microcapsules (90% packed capsules volume in Hanks) given in four separate doses over 2 successive days. The increase in abdominal volume as a result of the implantation dissipated with time, returning to normal size in 48 hours. All experiments and techniques were performed according to Canadian Animal Ethics guidelines.
Immunoassays. Blood samples were taken periodically from the tail vein through heparinized capillary tubes. Plasma was obtained and stored at -20°C. Both hFIX and anti-hFK antibodies were detected by enzyme-linked immunosorbent assay (ELISA). For the detection of hFUI, microtiter plates were coated at 37°C for 2 hours with 200 nglwell of monoclonal antibody against hFIX FXC008 (Boehringer Mannheim, Montreal, Canada) in l00 pL of 0.1 m o m Na2C03 pH 9.6. After blocking with 5% blotto (skim milk powder) at 4°C for 18 hours, each well was incubated with 100 pL of mouse plasma ( 1 5 dilution in 5% blotto) at 37°C for 1 hour. Human FIX bound to the wells was detected by incubating with rabbit anti-hFIX (Hoesht, Montreal, Canada) diluted 1: 1,000 in 5% blotto at 37°C for 1 hour, followed by goat antirabbit IgG-AP (BRL, Burlington, Canada) diluted 1:1,000 in 5% blotto at 37°C for 1 hour. The substrate para-nitrophenylphosphate (Sigma) at 1.5 mg/mL was added, incubated at 37°C for 1 hour, and the absorbance at 405 nm determined using a Titertek Multiskan PLUS MKII (Labsystems, Helsinki, Finland) ELISA plate reader. Pooled human plasma (containing 5 pg of factor WmL) was used as the standard for hFIX. For detection of antihuman factor IX antibodies raised in mice, Nunc maxisorb microtiter plates (GIBCO) were coated with 50 ng of purified hFIX in 100 pL of 0.1 m o m Na2C03, pH 9.6, per well and incubated at 37°C for 2 hours. The wells were washed with phosphate-buffered saline/Tween (PBS/T; 0.1 mol/L Na,HPO,, 0.15 m o a NaCI, 0.05% Tween 20, pH 7.4). and then blocked with 5% blotto (skim milk powder) in PBS/T at 4°C for 18 hours. After washing, 100 pL of mouse plasma (diluted I :300 in 5% blotto) per well was incubated at 37°C for 2 hours. After washing, 100 pL/well of goat antimouse IgG conjugated to alkaline phosphatase (Promega, Madison, WI) diluted 1:1,OOO in 5% blotto was incubated at 37°C for 1 hour. Following four washes, 100 pL of para-nitrophenylphosphate (Sigma) at a concentration of 1.5 mg/mL was added to each well as a chromogenic substrate. After incubation at 37°C for 1 hour, the absorbance of each well at 405 nm was read using a Titertek Multiskan PLUS MKII (Labsystems) ELISA plate reader. Plasma of mice immunized with 15 pg of purified hFIX given in three doses with Freund's adjuvant was included as a positive control in each assay.
Retrieval of implanted microcapsules. Animals were anesthetized with isofluorane, and sterile saline forcibly flushed through a small abdominal incision into the peritoneal space to create a current carrying out the capsules. If the animal was to be maintained, the abdominal wound was closed with surgical sutures (2-0). The whole procedure took less than 10 minutes to complete. The retrieved capsules were then resuspended in warm phosphate buffered saline and washed several times to eliminate free peritoneal macrophages and lymphocytes, which were usually retrieved with the capsules. The hFIX secretion by the encapsulated cells was determined by sampling media aliquots at timed intervals. For releasing the encapsulated cells, a sample of microcapsules was placed on a slide with trypan blue and, after gentle pressure was applied with a coverslip, the microcapsules were broken to release the enclosed cells. The number of cellslcapsule was counted and cell viability determined by trypan blue exclusion. A sample of released cells was regrown in culture. Once confluent, the cells were assayed again for hFIX secretion in vitro.
Clearance of hFIX from mouse plasma. Cohorts of mice were each injected intraperitoneally (IP) once with 6 pg of purified hHX. Animals were bled at regular intervals for 24 hours after the injection, and the blood samples assayed for hFIX by ELISA.
Western blotting. Mouse C2C12 and MLhFIX-5D5 recombinant cells (4 X IO6 cells) were harvested after a 24-hour culture in the absence of serum, resuspended in 100 pL of lysis buffer (50 mmoU L Tris-HCI, pH 8.0, 150 mmol/L NaC1, 0.02% sodium azide, 100 pg/mL phenylmethylsulfonyl fluoride [PMSF], 1 pg/mL aprotinin, 1% Triton X-100). and the suspension freeze-thawed three times to lyse the cells. After centrifugation (Eppendorf) for 30 minutes at 14,000 rpm, the supernatant was stored until needed. Proteins in the cell culture medium of harvested cells were precipitated with 0.1% trichloroacetic acid. Samples were incubated at 4°C for 1 hour and centrifuged for 5 minutes at 14,000 rpm. The pellet was washed twice with acetone, vacuum dried, and resuspended in loading buffer before electrophoresis. Protein samples were subjected to electrophoresis in a 12.5% acrylamide sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions. The proteins were then transferred onto nitrocellulose paper (Bio- For detection of mouse IgG against hFIX, the membranes were incubated with mouse plasma diluted 1:100 in 1 % blotto overnight, followed by incubation with goat antimouse IgG ( I :7,500 dilution in 1 % blotto) conjugated to alkaline phosphatase (Promega) for 1 hour, and color was developed as described before.
RESULTS
Secretion of human factor IX from encapsulated m y blasts. Forty-eight C2C12 clones transfected with pLIXSNL were isolated after G418 selection and screened for their hFIX secretion and vigorous growth. Clone MLhFIX-5D5 secreted on average 304 -+ 49 ng of factor IX per 1 0" celIs/24 hours as myoblasts and 173 t 47 ng/24 hours as myotubes derived from IO" undifferentiated myoblasts. Western blotting analysis with affinity purified sheep antihFIX IgG showed that recombinant hFIX of Mr =60,000 was the primary species of hFIX secreted from the transfected MLhFIX-5D5 clone. Human FIX was not detected in cell lysate of the transfected cells nor in the media from the nontransfected C2C12 cells (Fig l) . On encapsulation, the recombinant myoblasts continued to secrete hFIX at a rate of 285 ng/lO" ceIls/24 hours as determined 24 hours postencapsulation.
Delivery of human factor IX in mice. Normal C57BLl6 mice (n = 4) were implanted IP with microcapsules containing 5 X IO" viable recombinant myoblasts. A maximum of 3.8 ng/mL of human FIX was detected in plasma on day 2, decreasing thereafter to undetectable levels by day 14 (Fig 2) . A second group of mice (n = 2) implanted with microcapsules containing 8 X 10-5 viable recombinant myoblasts had 1.5 and I . 1 ng hFIX/mL of mouse plasma on day 2, and hFIX was undetectable by day 7 (Fig 2) . The third group of control mice (n = 4) injected IP with 5 X IO" unencapsulated recombinant myoblasts had no detectable hFIX in their plasma. Thus, without the protection of the microcapsules, the nonautologous recombinant cells were unable to deliver hFIX in vivo.
Development of anti-hFIX antibodies in mice. Because the delivery of xenogeneic hFIX into mice could elicit an antibody response, production of anti-hFIX antibodies was monitored. At 2 to 4 weeks postimplantation, low titer antihFIX was detected in mice with either encapsulated or nonencapsulated recombinant cells. However, only the mice implanted with encapsulated cells subsequently showed sustained antibody titer until the end of the experiment (day 213), while the titer of anti-hFIX in mice receiving unencapsulated cells remained at the initial low levels (Fig 3) . The .. Time post-implantation (days)
sustained antibody titer in the plasma of mice implanted with microcapsules suggested a basal ongoing hFIX delivery in vivo, although not enough to be detectable in plasma after day 14. The presence of antibodies against hFIX in plasma of implanted mice was confirmed by Western blotting. Plasma from mice implanted with microcapsules for 63 to 213 days showed antibodies that reacted specifically with purified hFIX while preimplantation plasma showed no reac- tion (Fig 4) . This finding was reproduced when C57BLl6 mice were implanted with encapsulated myoblasts transfected with a 0-actin promoter-driven hFIX construct (Fig 4) .
Detection of hFIX in mouse plasma. It was possible that the circulating anti-hFIX antibodies accelerated the clearance of the recombinant hFIX delivered into mice to render hFIX undetectable in the ELISA test. To test this hypothesis, we injected 6 pg of purified hFIX into three mice (mice B, C, and D from Fig 3) that had been implanted with encapsulated recombinant myoblasts on day 213 postimplantation when hFIX was no longer detectable in plasma (group A), and into three mice implanted with encapsulated mouse Ltkfibroblasts not secreting hFIX (group B). As a control, 6 pg of hFIX was injected IP into three naive mice (group C). As shown in Fig 5, hFIX was gradually cleared from the circulation of the naive mice (group C) from 41 ng/mL at 3 hours to 19 ng/mL at 24 hours (a clearance rate of -50% from 3 hours to 24 hours). In mice implanted with capsules containing non-hFIX-secreting cells (group B), the level of hFIX detected was initially lower than that of the naive mice (24 ng/mL at 3 hours), indicating that the implanted capsules Presence of antibodies against hFlX in the mice implanted with microencapsulated hFlX-secreting myoblasts. Purified hFlX (500 ng) was electrophoresed on SDS-PAGE and transferred for Western blotting using 1:lOO diluted plasma from mice implanted for 63 days with encapsulated MPhFIX-D6 myoblasts (hFIX driven by the p-actin promoter) or 213 days with encapsulated MLhFIX-5D5 myoblasts (hFIX driven by the viral LTR promoter, mouse D in Figs 2 and 3) . The anti-hFIX titer (DxlDol in these plasma samples, as described in Fig 3, was 10 .6 (MphFIX-D61 and 3.38 (MLhFIX-5D51. Anti-hFIX antibodies in the plasma samples bound t o the hFlX were detected with goat antimouse IgG-alkaline phosphatase and color developed with chromogenic substrate as described in Materials and Methods. The preimplantation plasma (Day 01 was used as control. Markers are expressed in kD. may have an absorption effect in reducing the initial amount of hFIX delivered to the plasma. However, once it had been delivered to the plasma, the exogenous hFIX was also cleared to about 50% of its level at 3 hours (from 24 ng/ mL at 3 hours to 19 ng/mL at 24 hours), indicating that microcapsules containing non-hFIX-secreting cells had no effect on the clearance rate of exogenous hFIX. In contrast, in mice implanted with hFIX-secreting capsules (Group A), only residual levels of hFIX (-6 ng/mL) were detected throughout the 24-hour period without decline. In fact, one mouse (C) had undetectable hFIX even at 3 hours, while another mouse (D) had barely detectable hFIX at 3 hours (<l ng/mL), and undetectable levels thereafter. Although the time course did not permit a determination of the circulating half-life of hFIX, these results indicate that the clearance of hFIX in plasma is accelerated in mice with encapsulated hFIX-secreting cells, thus suggesting that antibodies may play a role in increased clearance of hFIX from plasma.
We also investigated the in vitro effect of anti-hFIX antibodies in the ELISA assays for hFIX (Fig 6) . Human normal plasma containing 5 pg/mL of hFIX was added to mouse plasma samples that either did or did not contain anti-hFIX antibodies. The amount of detectable hFIX in the sample was dramatically reduced by anti-hFIX antibodies from a mouse immunized with hFIX. The same effect was observed with plasma from mice implanted with microencapsulated hFIX-secreting MOhFIX-D6 cells matched in anti-hFIX titer to mice B, C, and D in Fig 3, whose pooled plasma also showed a similar suppression effect (54% and 72% suppression, when 222 and 1 1 I pg of hFlX were added, respectively). These results indicated that anti-hFIX antibodies competed for hFlX binding to the coating antibody in ELISA, thus leading to an underestimation of the concentration of hFlX in the plasma samples by =SO% (Fig 6) . Therefore, the detection of hFIX in plasma of implanted mice was unreliable and underestimated after the first 2 weeks, following the development of an antibody response to the xenogeneic protein.
Retriewl of capsules from implanted mice. Samples of implanted microcapsules were retrieved from the animals at timed intervals to ascertain the durability and biocompatibility of the capsules and the in vivo survival of and hFlX secretion by the encapsulated myoblasts (Fig 7) . The microcapsules retrieved on days 7 (data not shown), 28, 84, and 2 I3 postimplantation appeared intact, free from fibrosis, and smooth on the surface. Most of the enclosed cells (60% to 65%) remained viable, compared with an initial viability of 70% at implantation. The myoblasts had proliferated in vivo within the microcapsular space from 78 cells per capsule on implantation to 108 on day 7 (data not shown) and 123 on day 28. The number of cells/capsule remained unchanged HORTELANO ET AL after day 28, suggesting no further cell proliferation. The microcapsules were cultured in vitro on retrieval to ascertain the rate of hFlX secretion. Neither implantation in vivo nor in vitro culturing of recovered cells influenced the rate of hFlX secretion which ranged from 21 1 to 301 ng/lO" cells/ 24 hours, compared with 285 ng/lOh ceIls/24 hours at day 0.
DISCUSSION
This study demonstrated that C2C12 myoblasts engineered to secrete hFlX can be implanted into normal mice to deliver hFIX systemically (Fig l ) . Although C2C12 myoblasts have been used to deliver hFIX in mice"." even at therapeutic levels,'' either immune suppression of the allogeneic hosts or use of nude mice was necessary to prevent graft rejection. Our protocol clearly demonstrated the efficacy of immuno-isolation to protect allogeneic cells from such rejection. Therefore, the feasibility of using nonautologous cells to deliver FIX provides a potential new approach for the genetic treatment of hemophilia B and an alternative to ex vivo protocols using myoblasts,"'".' ' keratinocytes," or fibroblast~'~ for autologous implantation or in vivo protocols using viral particles for direct injection.'"
To treat hemophilia B successfully using gene therapy, both physiologically relevant levels and long-term delivery of biologically active hFIX into the circulation are necessary. The maximum level of hFIX delivered in the present vectormyoblast combination, was only =4 ng/mL (Fig 2) or 0. I % of normal physiologic level in humans. Hence, for this protocol to become clinically relevant, the level of expression must be improved by using more efficient vector^,'^ and/or stronger and more appropriate promoter-enhancers.2' However, delivery of even 3 to I O ng/mL FIX in hemophilia B dogs reduced the whole blood clotting time by SO%." Therefore, the low level of FIX delivered by the current protocol may be an effective prophylactic treatment for hemophilia B, even though a physiologic level of FIX delivery is yet to be achieved.
The requirement for sustained hFIX delivery was more difficult to attain, as the level of hFlX delivered in mice had decreased to undetectable levels by day 14 (Fig 2) . Similar transient delivery of hFlX has been reported using various protocols for hFIX delivery in vivo.17~~1~2'~zx~~y~3" An in vivo downregulation of viral promoter (MO MLV S' LTR in MLhFIX-SDS) may be responsible for the transient expression. Inhibition in vivo of LTR-driven FIX or FVIlI expression has been reported for fib rob last^'^."^^' and hematopoietic cells33 and was suggested for keratinocytes secreting FIX." Dai et al" also described a similar pattern of dog FIX delivery in mice using myoblasts, when expression of the FIX cDNA was under the viral LTR promoter control. However, a long-term delivery of FIX in vivo (> l80 days) was achieved when a myoblast-specific enhancer (MCK) was introduced in the retroviral construct." Thus, a judicious choice of promoter/enhancer elements may be critical for the long-term success of gene therapy protocols based on recombinant cells.
Microcapsules containing the recombinant cells retrieved after 213 days of implantation secreted hFlX at similar rates as those of the preimplantation microcapsules 7 " l" Retrieval of microcapsules postimplantation. Microcapsules were retrieved from the abdominal cavities of implanted mice by lavage at various time points postimplantation. The integrity and appearance of the microcapsules were recorded with dark-field photomicrography. The retrieved capsules were washed, kept under regular tissue culture condition overnight, and assayed for rates of hFlX secretion into the media the next day. For viability and cell count, the microcapsules were ruptured t o release the cells as described in Material and Methods. Cells regrown in vitro from the retrieved microcapsules secreted hFlX at preimplantation levels (data not shown). Scale Bar = 500 pm. (Fig 7) . Our data indicated that the microcapsules reagainst xenogeneic hFIX delivered i n vivo was demonmained permeable to FIX in vivo after prolonged implanstrated by Palmer et al" and thought to be responsible for tation and that the encapsulated myoblasts-myotubes rethe disappearance of hFIX from plasma of normal mice.'' tained their capacity to secrete recombinant gene products
We present data to show that. after day 14. anti-hFIX at an undiminished rate. The presence of antibodies antibodies were detected at sustained titers for at least 200
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